Product Pipeline
Xenon is focused on advancing our ion channel neurology pipeline.
The products within our novel proprietary pipeline – including clinical-stage candidates XEN496 and XEN1101 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.
XEN496
for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
NBI-921352
for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences
PCRX301
for Post-Operative Pain
Partnered with Pacira BioSciences
